Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00047489
Status:
COMPLETED
Last Update Posted:
2018-10-31
First Post:
2002-10-08
Brief Title:
Study of ABT-751 in Patients With Refractory Hematologic Malignancies
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
A Phase I Study of ABT-751 in Patients With Refractory Hematologic Malignancies
Status:
COMPLETED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
ABT-751 is a new antitumor drug that that interferes with cell division The goal of this clinical research study is to find the highest safe dose of ABT-751 that can be given as a treatment for refractory hematologic malignancies The safety and side effects of ABT-751 will also be studied
Detailed Description:
The current low cure rates in most patients with advanced hematologic cancers indicate the need to identify new agents that can be incorporated with current therapies to improve prognosis The vinca alkaloids are effective broad-spectrum anti-leukemic drugs Microtubules are a major structural component of cells They play a role in cell shape cellular polarity cellular movement intracellular transport and the segregation of chromosomes during mitosis The cellular microtubule dynamics are highly regulated As cells enter mitosis the interphase microtubules disappear and are replaced with a new network of microtubules that interact with the mitotic spindle Disruption of these new microtubules leads to cell cycle arrest These important and highly labile microtubule arrays comprising the mitotic spindle are the principal target of oncologic antimitotic compounds Known antimitotic agents fall into three classes the vinca alkaloids vincristine vinblastine and vinorelbine taxanes paclitaxel and docetaxel and colchicine-site binders There are no colchicine-site agents currently approved for cancer chemotherapy These three classes of compounds have distinct binding sites on the tubulin subunits ABT-751 is a novel orally administered antimitotic agent that binds to the colchicine site on beta-tubulin and inhibits polymerization of microtubules
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None